Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 464 of the 467 references it cites were found in a registry or an index.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Open access

Abstract

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publication of clinical practice guidelines without commercial support, and members volunteer their time to the writing and review efforts. Clinical practice guidelines provide recommendations applicable to patients with or at risk of developing cardiovascular disease (CVD). The focus is on medical practice in the United States, but these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer decisions, the intent is to improve quality of care and align with patients’ interests. Guidelines are intended to define practices meeting the needs of patients in most, but not all, circumstances, and should not replace clinical judgment. Recommendations for guideline-directed management and therapy, which encompasses clinical evaluation, diagnostic testing, and both pharmacological and procedural treatments, are effective only when followed by both practitioners and patients. Adherence to recommendations can be enhanced by shared decision-making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated conditions and comorbidities. The ACC/AHA Task Force on Clinical Practice Guidelines strives to ensure that the guideline writing committee both contains requisite expertise and is representative of the broader medical community by selecting experts from a broad array of backgrounds, representing different geographic regions, sexes, races, ethnicities, intellectual perspectives/biases, and scopes of clinical practice, and by inviting organizations and professional societies with related interests and expertise to participate as partners or collaborators. The ACC and AHA have rigorous policies and methods to ensure that documents are developed without bias or improper influence. The complete policy on relationships with industry and other entities (RWI) can be found online. Beginning in 2017, numerous modifications to the guidelines have been and continue to be implemented to make guidelines shorter and enhance “user friendliness.” Guidelines are written and presented in a modular knowledge chunk format, in which each chunk includes a table of recommendations, a brief synopsis, recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyperlinked references are provided for each modular knowledge chunk to facilitate quick access and review. More structured guidelines–including word limits (“targets”) and a web guideline supplement for useful but noncritical tables and figures–are 2 such changes. This Preamble is an abbreviated version, with the detailed version available online. The reader is encouraged to consult the full-text guideline(P-1) for additional guidance and details, since the executive summary contains mainly the recommendations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000000625

Cites

464 of 464 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

21 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 467 references

Research works printed but not linked: 110

  1. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  2. 10.1016/j.jacl.2012.04.081 · DOI
  3. 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
  4. 10.1016/j.jacc.2014.02.615 · DOI · Paper page
  5. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  6. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.
  7. 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
  8. 10.1056/nejmoa1410489 · DOI · Paper page
  9. 10.1056/nejmoa1615664 · DOI · Paper page
  10. 10.1056/nejmoa1410489 · DOI · Paper page
  11. 10.1056/nejmoa061894 · DOI · Paper page
  12. 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
  13. 10.1016/s0140-6736(16)31357-5 · DOI · Paper page
  14. 10.1056/nejm199610033351401 · DOI · Paper page
  15. 10.1056/nejm199811053391902 · DOI · Paper page
  16. 10.1056/nejmoa1410489 · DOI · Paper page
  17. 10.1056/nejmoa1701131 · DOI · Paper page
  18. 10.1056/nejmoa1615664 · DOI · Paper page
  19. 10.1161/cir.0000000000000626 · DOI
  20. 10.1056/nejm199811053391902 · DOI · Paper page
  21. 10.1056/nejm199511163332001 · DOI · Paper page
  22. 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
  23. 10.1056/nejmoa1410489 · DOI · Paper page
  24. 10.1001/jama.2016.13985 · DOI · Paper page
  25. Kastelein, JJ, Ginsberg, HN, Langslet, G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996–3003.
  26. 10.1016/j.jacc.2016.11.070 · DOI · Paper page
  27. 10.2337/dc05-2415 · DOI · Paper page
  28. 10.1001/jama.2014.2630 · DOI · Paper page
  29. 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
  30. 10.1056/nejmoa0807646 · DOI · Paper page
  31. 10.1056/nejmoa1410489 · DOI · Paper page
  32. 10.1001/jama.2016.13985 · DOI · Paper page
  33. 10.1056/nejmoa1410489 · DOI · Paper page
  34. 10.1016/j.jacc.2016.03.519 · DOI · Paper page
  35. 10.1001/jama.2014.2630 · DOI · Paper page
  36. 10.1161/01.cir.0000437740.48606.d1 · DOI · Paper page
  37. 10.1161/01.cir.0000437739.71477.ee · DOI · Paper page
  38. 10.1056/nejmoa1200303 · DOI · Paper page
  39. 10.1161/01.atv.0000238352.25222.5e · DOI · Paper page
  40. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  41. 10.1001/jama.2014.2630 · DOI · Paper page
  42. 10.1161/circulationaha.108.816694 · DOI · Paper page
  43. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  44. 10.1056/nejmoa1600176 · DOI · Paper page
  45. 10.1016/j.jacc.2015.07.066 · DOI · Paper page
  46. 10.1001/jamacardio.2016.5493 · DOI · Paper page
  47. 10.1093/eurheartj/ehy217 · DOI · Paper page
  48. 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
  49. 10.1016/s0140-6736(11)60739-3 · DOI · Paper page
  50. Chou R Dana T Blazina I et al. Statin use for the prevention of cardiovascular disease in adults: a systematic review for the US Preventive Services Task Force.. Rockville MD: US Agency for Healthcare Research and Quality 2016. Report No.: 14-05206-EF-2.
  51. 10.1001/jama.279.20.1615 · DOI · Paper page
  52. 10.1056/nejmoa0807646 · DOI · Paper page
  53. 10.1056/nejmoa1600176 · DOI · Paper page
  54. 10.1001/jama.2016.13985 · DOI · Paper page
  55. 10.1016/j.jacc.2014.06.1186 · DOI · Paper page
  56. 10.1001/jama.2014.2630 · DOI · Paper page
  57. 10.1016/j.jacc.2016.05.084 · DOI
  58. 10.1016/j.jacc.2015.07.066 · DOI · Paper page
  59. 10.1161/circoutcomes.110.959247 · DOI · Paper page
  60. 10.1093/eurheartj/ehy217 · DOI · Paper page
  61. 10.1016/s0140-6736(06)69472-5 · DOI · Paper page
  62. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  63. 10.1001/jamacardio.2016.4494 · DOI
  64. 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
  65. 10.1016/j.amjcard.2014.07.043 · DOI
  66. 10.1001/jamacardio.2016.5493 · DOI · Paper page
  67. 10.3349/ymj.2017.58.1.82 · DOI
  68. 10.1016/s0735-1097(17)35217-8 · DOI
  69. 10.1016/j.jcmg.2016.03.022 · DOI
  70. 10.1001/jama.2015.7515 · DOI
  71. 10.1161/circulationaha.115.016846 · DOI
  72. 10.1016/j.ahj.2009.08.007 · DOI · Paper page
  73. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  74. 10.1056/nejmoa0807646 · DOI · Paper page
  75. 10.1161/circulationaha.117.028271 · DOI
  76. 10.1056/nejmoa1600176 · DOI · Paper page
  77. 10.1016/s0140-6736(12)60367-5 · DOI · Paper page
  78. 10.1016/j.jcmg.2016.03.022 · DOI
  79. 10.1016/j.jacc.2016.05.084 · DOI
  80. 10.1007/s11096-015-0147-7 · DOI
  81. 10.1001/jamacardio.2017.2543 · DOI
  82. 10.1001/jamacardio.2016.5493 · DOI · Paper page
  83. 10.1161/circulationaha.116.022335 · DOI · Paper page
  84. 10.1016/j.jacc.2014.01.060 · DOI · Paper page
  85. 10.1001/jamacardio.2016.4494 · DOI
  86. 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
  87. 10.1001/jama.2014.2630 · DOI · Paper page
  88. 10.1016/j.jacc.2016.02.055 · DOI · Paper page
  89. Alluri, K, McEvoy, JW, Dardari, ZA, et al. Distribution and burden of newly detected coronary artery calcium: results from the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Comput Tomogr. 2015;9:337–344.e1. · DOI
  90. 10.1016/s0140-6736(06)69472-5 · DOI · Paper page
  91. Kimura, T, Inoue, T, Taguchi, I, et al. Does high-intensity pitavastatin therapy further improve clinical outcomes? The REAL-CAD study in 13 054 patients with stable coronary artery disease. Circulation 2017:136;e450.
  92. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  93. 10.1016/s0140-6736(12)60367-5 · DOI · Paper page
  94. 10.1016/s2213-8587(16)30156-5 · DOI · Paper page
  95. 10.1016/s0140-6736(11)60739-3 · DOI · Paper page
  96. 10.1001/jamacardio.2016.4494 · DOI
  97. 10.1002/14651858.cd009217.pub2 · DOI · Paper page
  98. 10.1016/j.jacc.2015.01.043 · DOI
  99. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
  100. 10.1016/j.jacc.2016.03.519 · DOI · Paper page
  101. 10.1016/s0140-6736(10)61350-5 · DOI · Paper page
  102. 10.1016/s0140-6736(16)31357-5 · DOI · Paper page
  103. 10.1056/nejmoa1600176 · DOI · Paper page
  104. 10.1161/01.cir.0000437741.48606.98 · DOI · Paper page
  105. 10.1056/nejmoa1615664 · DOI · Paper page
  106. 10.1016/j.jacc.2017.10.001 · DOI
  107. 10.1016/j.jacc.2016.09.928 · DOI
  108. 10.1001/jama.2016.11004 · DOI · Paper page
  109. 10.1002/clc.22535 · DOI
  110. 10.1161/01.cir.0000437738.63853.7a · DOI · Paper page

Cited by

See all 6,185

Metadata

Authors
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., Saseen, J. J., Smith, S. C., Sperling, L., Virani, S. S., & Yeboah, J.
Affiliations
ACC/AHA Representative. †AACVPR Representative. ‡ACC/AHA Task Force on Clinical Practice Guidelines Liaison. §Prevention Subcommittee Liaison. ‖PCNA Representative. ¶AAPA Representative. **AGS Representative. ††ADA Representative. ‡‡PM Representative. §§ACPM Representative. ‖‖NLA Representative. ¶¶APhA Representative. ***ASPC Representative. †††ABC Representative.
Venue
Circulation
Published
2019-06-18
Volume
139
Issue
25
Pages
e1082-e1143
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2900034165
Cited by
6,185
References
467
Citations by year
2026: 244 · 2025: 582 · 2024: 988 · 2023: 1005 · 2022: 862 · 2021: 1014 · 2020: 891 · 2019: 571
FWCI
796.44
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
Funders
National Institute of General Medical Sciences (U54GM115428)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
cardiovascular disease prevention, LDL cholesterol, cardiovascular risk assessment, dyslipidemia, statins, PCSK9 inhibitors, ezetimibe, LDL-C lowering therapy, cardiovascular risk reduction, shared decision-making, guideline adherence, cardiovascular disease risk reduction
MeSH terms
Anticholesteremic Agents, Cardiology, Cardiovascular Diseases, Cholesterol, Humans, Hyperlipidemias, Risk Factors, Biomarkers, Treatment Outcome, Risk Assessment, Evidence-Based Medicine, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. https://app.cochat.ai/papers/10.1161/cir.0000000000000625
The paper
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., . . . Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. https://doi.org/10.1161/cir.0000000000000625

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.